Trial Profile
A Multicenter, Open-Label Single-Arm Study of YONDELIS (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2015
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary)
- Indications Sarcoma
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 24 Jan 2015 The protocol has been amended to exclude the drug OPT-821 in combination with trabectedin as reported by OHSU Health record.
- 07 Jun 2012 New trial record